| |
|
|
| |
|
|
| Contact |
|
Brück Wolfram |
| |
|
|
| Title |
|
In vitro activity of commercial probiotic Lactobacillus strains against uropathogenic Escherichia coli |
| |
|
|
| Author(s) |
|
Michèle Delley, Anne Bruttin, Michel Richard, Michael Affolter, Enea Rezzonico, Wolfram M Brück |
| |
|
|
| References |
|
FEMS Microbiology Letters, 2015 |
| |
|
|
| Url |
|
http://dx.doi.org/10.1093/femsle/fnv096 |
| |
|
|
| Abstract |
|
Urinary tract infection (UTI) is one of the most prevalent infections in humans. In ≥80% of cases, the etiologic agents are strains of uropathogenic Escherichia coli (UPEC), which commonly reside in the gastrointestinal tract. Lactobacilli have been shown to prevent UTI reoccurrence by restoring the urogenital microbiota when administered vaginally or orally. The goal of this study was to determine if commercial probiotic Lactobacillus spp. reduce or clear UPEC in vitro. Results show that it is likely that lactobacilli may, in addition to restoring a healthy urogenital microbiota through acidification of their environment, also displace adhering UPEC and cause a reduction of infection. |
| |
|
|
| |
|
|
| |
|
|
| |
|
|